Peptide	O
-	O
BSA	O
conjugates	O
as	O
diagnostic	O
antigens	O

To	O
analyse	O
the	O
potential	O
of	O
the	O
peptides	O
to	O
behave	O
as	O
antigen	O
mimics	O
,	O
their	O
ability	O
to	O
react	O
with	O
IgM	O
antibodies	O
from	O
individuals	O
infected	O
with	O
EBV	O
was	O
assessed	O
.	O

In	O
our	O
previous	O
study	O
,	O
we	O
demonstrated	O
that	O
the	O
sensitivity	O
of	O
detection	O
was	O
greatly	O
improved	O
when	O
the	O
peptides	O
were	O
coupled	O
to	O
a	O
carrier	O
molecule	O
such	O
as	O
BSA	O
prior	O
to	O
immobilisation	O
onto	O
a	O
solid	O
surface	O
(	O
Casey	O
et	O
al	O
.	O
,	O
2006	O
)	O
.	O

This	O
strategy	O
was	O
adopted	O
to	O
test	O
peptides	O
Eb1	O
-	O
4	O
and	O
H1	O
.	O

A	O
set	O
of	O
40	O
clinical	O
samples	B-Organism_substance
that	O
were	O
classified	O
as	O
EBV	O
seropositive	O
(	O
n	O
=	O
16	O
)	O
,	O
seronegative	O
(	O
n	O
=	O
16	O
)	O
or	O
potentially	O
cross	O
-	O
reactive	O
sera	B-Organism_substance
(	O
n	O
=	O
8	O
)	O
were	O
assessed	O
for	O
reactivity	O
with	O
Eb1	O
-	O
4	O
and	O
H1	O
peptides	O
individually	O
.	O

The	O
cut	O
-	O
off	O
level	O
was	O
defined	O
as	O
the	O
mean	O
optical	O
density	O
of	O
the	O
seronegative	O
samples	B-Organism_substance
plus	O
3	O
standard	O
deviations	O
shown	O
as	O
a	O
line	O
on	O
the	O
graphs	O
in	O
Fig	O
.	O

5	O
.	O

Readings	O
above	O
this	O
level	O
were	O
defined	O
as	O
positive	O
and	O
below	O
this	O
level	O
negative	O
.	O

The	O
same	O
set	O
of	O
samples	B-Organism_substance
were	O
analysed	O
on	O
BSA	O
alone	O
and	O
these	O
values	O
were	O
subtracted	O
from	O
the	O
peptide	O
-	O
BSA	O
conjugate	O
readings	O
and	O
the	O
corrected	O
absorbance	O
readings	O
were	O
plotted	O
individually	O
for	O
our	O
new	O
peptides	O
Eb1	O
-	O
4	O
and	O
H1	O
in	O
Fig	O
.	O

5	O
.	O

There	O
was	O
a	O
clear	O
difference	O
in	O
the	O
detection	O
of	O
seropositive	O
antibodies	O
by	O
all	O
the	O
peptides	O
(	O
Fig	O
.	O
5A	O
-	O
E	O
)	O
compared	O
with	O
the	O
analysis	O
of	O
BSA	O
alone	O
(	O
Fig	O
.	O
5F	O
)	O
,	O
with	O
the	O
majority	O
of	O
absorbance	O
readings	O
above	O
the	O
cut	O
-	O
off	O
level	O
.	O

We	O
compared	O
the	O
ability	O
of	O
our	O
panel	O
of	O
peptide	O
mimotopes	O
to	O
be	O
recognised	O
by	O
antibodies	O
in	O
the	O
same	O
set	O
of	O
seropositive	O
samples	B-Organism_substance
in	O
Fig	O
.	O

6A	O
and	O
the	O
sensitivity	O
of	O
detection	O
is	O
shown	O
in	O
Fig	O
.	O

6B	O
.	O

We	O
also	O
included	O
F1	O
and	O
Gp125	O
mimotopes	O
specific	O
for	O
two	O
mAbs	O
in	O
our	O
previous	O
study	O
(	O
Casey	O
et	O
al	O
.	O
,	O
2006	O
)	O
.	O

Of	O
the	O
peptides	O
identified	O
from	O
polyclonal	O
sera	B-Organism_substance
Eb1	O
,	O
Gp125	O
and	O
F1	O
had	O
the	O
highest	O
sensitivity	O
(	O
94	O
%	O
)	O
.	O

Slightly	O
lower	O
sensitivity	O
was	O
observed	O
for	O
Eb2	O
,	O
3	O
and	O
4	O
(	O
88	O
%	O
)	O
and	O
H1	O
peptide	O
had	O
the	O
lowest	O
sensitivity	O
(	O
81	O
%	O
)	O
as	O
summarised	O
in	O
Fig	O
.	O

6B	O
.	O

The	O
sensitivity	O
of	O
F1	O
and	O
Gp125	O
was	O
similar	O
to	O
that	O
produced	O
by	O
the	O
mimotopes	O
selected	O
in	O
our	O
previous	O
study	O
,	O
95	O
%	O
for	O
F1	O
and	O
92	O
%	O
for	O
Gp125	O
.	O

Fig	O
.	O

5	O

Evaluation	O
of	O
peptides	O
Eb1	O
-	O
4	O
and	O
H1	O
coupled	O
to	O
BSA	O
as	O
EBV	O
diagnostic	O
reagents	O
.	O

Human	O
serum	B-Organism_substance
(	O
n	O
=	O
40	O
)	O
previously	O
analysed	O
using	O
a	O
diagnostic	O
test	O
for	O
VCA	O
IgM	O
was	O
allowed	O
to	O
react	O
with	O
the	O
peptides	O
and	O
the	O
bound	O
IgM	O
antibodies	O
were	O
detected	O
using	O
anti	O
-	O
human	O
IgM	O
HRP	O
.	O

The	O
absorbance	O
readings	O
for	O
1	O
(	O
positive	O
)	O
,	O
2	O
(	O
negative	O
)	O
and	O
putative	O
cross	O
-	O
reactive	O
sera	B-Organism_substance
for	O
3	O
(	O
Parvo	O
)	O
,	O
4	O
(	O
HSV	O
)	O
,	O
5	O
(	O
CMV	O
)	O
and	O
6	O
(	O
RF	O
)	O
are	O
plotted	O
for	O
(	O
A	O
)	O
Eb1	O
,	O
(	O
B	O
)	O
Eb2	O
,	O
(	O
C	O
)	O
Eb3	O
,	O
(	O
D	O
)	O
Eb4	O
,	O
(	O
E	O
)	O
H1	O
and	O
(	O
F	O
)	O
BSA	O
,	O
respectively	O
.	O

The	O
cut	O
-	O
off	O
value	O
is	O
defined	O
as	O
the	O
mean	O
of	O
the	O
negative	O
population	O
+	O
3SD	O
indicated	O
by	O
a	O
solid	O
horizontal	O
line	O
;	O
since	O
there	O
were	O
no	O
false	O
positives	O
,	O
the	O
specificity	O
for	O
each	O
mimotope	O
was	O
100	O
%	O
.	O

Fig	O
.	O

6	O

Comparison	O
of	O
the	O
reactivities	O
of	O
our	O
panel	O
of	O
mimotopes	O
Eb1	O
-	O
4	O
,	O
H1	O
,	O
F1	O
and	O
Gp125	O
conjugated	O
to	O
BSA	O
with	O
EBV	O
IgM	O
-	O
positive	O
sera	B-Organism_substance
(	O
n	O
=	O
16	O
)	O
absorbance	O
values	O
are	O
plotted	O
and	O
the	O
cut	O
-	O
off	O
levels	O
are	O
depicted	O
by	O
a	O
horizontal	O
line	O
in	O
(	O
A	O
)	O
.	O

(	O
B	O
)	O
Summary	O
of	O
the	O
false	O
-	O
negative	O
results	O
from	O
the	O
5	O
/	O
16	O
serum	B-Organism_substance
samples	I-Organism_substance
seropositive	O
for	O
IgM	O
EBV	O
and	O
the	O
overall	O
sensitivity	O
for	O
each	O
mimotope	O
for	O
diagnosis	O
of	O
EBV	O
IgM	O
antibodies	O
.	O

We	O
also	O
considered	O
which	O
seropositive	O
EBV	O
samples	B-Organism_substance
contained	O
antibodies	O
that	O
did	O
not	O
recognise	O
the	O
panel	O
of	O
peptides	O
,	O
i	O
.	O
e	O
.	O
false	O
-	O
negative	O
readings	O
,	O
listed	O
in	O
Fig	O
.	O

6B	O
.	O

The	O
antibodies	O
in	O
serum	B-Organism_substance
1	O
(	O
s1	O
)	O
were	O
unreactive	O
with	O
all	O
of	O
the	O
peptides	O
identified	O
in	O
this	O
study	O
,	O
s2	O
was	O
not	O
reactive	O
with	O
Eb3	O
,	O
Eb4	O
and	O
H1	O
and	O
s3	O
was	O
unreactive	O
with	O
H1	O
.	O

Gp125	O
and	O
F1	O
that	O
were	O
selected	O
in	O
our	O
previous	O
study	O
were	O
recognised	O
by	O
s1	O
,	O
2	O
and	O
3	O
;	O
however	O
,	O
two	O
different	O
serum	B-Organism_substance
samples	I-Organism_substance
(	O
s4	O
and	O
5	O
)	O
did	O
not	O
recognise	O
F1	O
or	O
Gp125	O
,	O
respectively	O
.	O

This	O
demonstrates	O
that	O
individual	O
peptides	O
are	O
not	O
recognised	O
by	O
all	O
EBV	O
antibodies	O
and	O
confirms	O
that	O
different	O
peptides	O
are	O
required	O
to	O
represent	O
different	O
epitopes	O
.	O

Therefore	O
,	O
a	O
combination	O
of	O
Eb1	O
peptide	O
F1	O
and	O
Gp125	O
peptides	O
could	O
be	O
recognised	O
by	O
antibodies	O
present	O
in	O
all	O
this	O
set	O
of	O
EBV	O
clinical	O
samples	B-Organism_substance
resulting	O
in	O
100	O
%	O
sensitivity	O
.	O

For	O
the	O
samples	B-Organism_substance
defined	O
as	O
EBV	O
-	O
seronegative	O
,	O
there	O
were	O
no	O
readings	O
above	O
the	O
cut	O
-	O
off	O
level	O
and	O
therefore	O
no	O
false	O
positives	O
,	O
resulting	O
in	O
100	O
%	O
specificity	O
.	O

In	O
addition	O
,	O
there	O
were	O
no	O
absorbance	O
readings	O
above	O
the	O
cut	O
-	O
off	O
levels	O
for	O
the	O
potentially	O
cross	O
-	O
reactive	O
serum	B-Organism_substance
samples	I-Organism_substance
,	O
inferring	O
that	O
the	O
peptides	O
identified	O
in	O
this	O
study	O
have	O
high	O
specificity	O
for	O
EBV	O
antibodies	O
.	O

